Intercept's lead drug boasts success in PhIII after worrisome side-effects disclosure

Intercept Pharmaceuticals ($ICPT) delivered a bad news-good news punch over the weekend. Friday night, the company disclosed some serious heart-related adverse events in a study of its lead drug OCA (obeticholic acid). Sunday morning, the company offered an upbeat counterpoint, with some positive Phase III data on the drug. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.